Bayer, Onyx finish enrollment in Nexavar phase 3 trials

By Elaine Rigoli

Tampa, Fla., May 3 - Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc. announced the completion of patient enrollment in two randomized, double-blind phase 3 clinical trials.

The first trial will administer Nexavar (sorafenib) tablets with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma. The second trial will administer Nexavar as a single agent in patients with advanced hepatocellular carcinoma, or liver cancer.

"Therapy with Nexavar could potentially provide an important advancement in the treatment of these difficult diseases, and we are pleased to have reached these milestones," said Henry Fuchs, executive vice president and chief medical officer of Onyx, in a statement.

"While the studies are still ongoing and analyses will not commence until the pre-specified number of events are reached, we look forward to generating randomized data in these indications."

Based in Emeryville, Calif., Onyx is engaged in the development of novel cancer therapies.

Bayer Pharmaceuticals is part of the worldwide operations of Bayer HealthCare AG, a subsidiary of Bayer AG.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.